Ronald Muhlenkamp (Trades, Portfolio), the founder and president of Muhlenkamp & Co. Inc., bought shares of the following stocks in the first quarter.
The guru boosted his Express Scripts Holding Co. (ESRX, Financial) position by 114.36%, impacting the portfolio by 1.73%.
The pharmacy benefits manager has a market cap of $41.14 billion and an enterprise value of $53.81 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 27.30% and return on assets of 8.82% are outperforming 85% of companies in the Global Health Care Plans industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.16 is below the industry median of 1.15.
The company's largest shareholder among the gurus is Dodge & Cox with 6.23% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 2.56% and Richard Pzena (Trades, Portfolio) with 0.55%.
The investor increased his AutoZone Inc. (AZO, Financial) holding by 59.95%, expanding the portfolio 0.96%.
The auto parts retailer has a market cap of $17.6 billion and an enterprise value of $22.35 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. Its ROA of 14.53% and return on capital of 48.15% are outperforming 82% of companies in the Global Specialty Retail industry. Its financial strength is rated of 4 out of 10. The cash-debt ratio of 0.06 is below the industry median of 1.02.
Manning & Napier Advisors is the company's largest shareholder among the gurus with 0.39% of outstanding shares, followed by Tweedy Browne (Trades, Portfolio) with 0.39% and Joel Greenblatt (Trades, Portfolio) with 0.15%.
Muhlenkamp boosted his holding of Naspers Ltd. (NPSNY, Financial) by 61.16%. The transaction had an impact of 0.96% on the portfolio.
The multinational media company has a market cap of $112.67 billion and an enterprise value of $114.56 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. Its ROE of 23.82% and ROA of 15.79% are outperforming 84% of companies in the Global Internet Content and Information industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.68 is below the industry median of 7.64.
Muhlenkamp is the largest shareholder of the company among the gurus with 0.01% of outstanding shares.
The guru invested in 187,742 of Alerian MLP (AMLP, Financial), expanding the portfolio 0.64%.
Alerian is an exchange-traded fund that provides exposure to the Alerian MLP Infrastructure Index (AMZI), which is a float-adjusted, capitalization-weighted composite of energy infrastructure Master Limited Partnerships that are involved in midstream operations.Â
The guru added 19.93% to his PowerShares BuyBack Achievers Portfolio (PKW, Financial) position. The transaction had an impact of 0.12% on the portfolio.
The ETF reflects the performace of the Mergent Buyback Achievers Index, which tracks U.S. companies that have purchased at least 5% of its outstanding shares in a 12-month period.
The guru increased his Cognizant Technology Solutions Corp. (CTSH, Financial) holding by 3.57%. The transaction had an impact of 0.1% on the portfolio.
The information technology consultant, which provides application outsourcing, systems integration, business process services and cloud services, has a market cap of $44.21 billion and an enterprise value of $40.15 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. Its ROE of 13.81% and ROA of 10.13% are outperforming 72% of companies in the Global Information Technology Services industry. Its financial strength is rated 8 out of 10. The cash-debt ratio of 6.25 is below the industry median of 8.37.
The largest guru shareholder of the company is Pzena with 1.14% of outstanding shares, followed by Pioneer Investments (Trades, Portfolio) with 0.76% and Jeremy Grantham (Trades, Portfolio) with 0.66%.
The Bristol-Myers Squibb Co. (BMY, Financial) position was boosted by 2.21%, impacting the portfolio by 0.09%.
The biopharmaceutical company has a market cap of $85.49 billion and an enterprise value of $86.53 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. While its ROE of 6.71% is outperforming the sector, its ROA of 2.75% is underperforming 52% of companies in the Global Drug Manufacturers - Major industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 0.88 is below the industry median of 3.53.
The Vanguard Health Care Fund (Trades, Portfolio) is the company's largest shareholder among the gurus with 2.86% of outstanding shares, followed by Dodge & Cox with 1.7% and Jim Simons (Trades, Portfolio) with 0.89%.
Muhlenkamp increased the Celgene Corp. (CELG, Financial) position by 3.41%. The trade had an impact of 0.08%.
The company discovers and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. It has a market cap of $59.42 billion and an enterprise value of $74.95 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. Its ROE of 37% and ROA of 9.04% are outperforming 91% of companies in the Global Biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.23 is below the industry median of 73.06.
The company's largest guru shareholder is Spiros Segalas (Trades, Portfolio) with 0.54% of outstanding shares, followed by Simons with 0.35%, David Rolfe (Trades, Portfolio) with 0.13% and Pioneer Investments with 0.12%.
Disclosure: I do not own any stocks mentioned in this article.
Also check out:
